EUCTR2006-001548-30-SK进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III study to assess the efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in patients with grass pollen-related allergic rhinoconjunctivitis
Artu Biologicals Europe B.V.0 个研究点目标入组 600 人开始时间: 2006年8月10日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The inclusion criteria are to be verified at the Screening Visit and reviewed at Visit 1. In order for the patient to be enrolled in this study, he / she has to meet the following criteria:
- •1.Male or female out-patients aged 18 to 50 years (inclusive).
- •2.Patients with grass pollen-related allergic rhinoconjunctivitis for at least the last 2 pollen seasons.
- •3.Sensitised to the centre-specific grass pollen families as demonstrated by a positive skin prick test (wheal diameter more than 3 mm larger than the diluent control) and IgE value of at least Class II.
- •4.A RRTSS of greater than or equal to 14 during the pollen season prior to the start of the study.
- •5.Patients must be in general good health as determined by past medical history, physical examination, 12-lead ECG and safety laboratory tests.
- •6.Patients with a normal spirometry. Forced expiratory volume in 1 second (FEV1) at least 80% of the predicted value at Screening.
- •7.Patients who have been informed of the nature and aims of the study and have given their written consent / assent to participate in this study in accordance with local laws and requirements.
- •8.Patients who are willing to comply with the protocol and understand the information given and the text of the consent form.
- •9.Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method (for example, hormonal birth control [orally, injectable or by implant, for at least 2 months before enrolment], intrauterine device, spermicide used with male condom, bilateral tubal ligation, diaphragm used with spermicide, female condom, monogamous relationship with vasectomised partner).
- •Note: Female patients are considered not to have childbearing potential before their menarche, at least 2 years after menopause or if they have had a total hysterectomy, bilateral oophorectomy or ovariectomy.
- •10.Negative urine pregnancy test if female.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnancy, breast-feeding / lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method.
- •2.Asthma requiring treatment other than beta-2 inhaled agonists. Patients with intermittent asthma not necessitating inhaled or systemic corticoid treatment may be included.
- •3.Patients who have taken oral steroids within 12 weeks before the Screening Visit.
- •4.Patients who have received desensitisation treatment for grass pollen.
- •5.Treatment by immunotherapy with any other allergen within the previous 5 years.
- •6.Patients who have suffered a lower respiratory tract infection within 4 weeks or an upper respiratory tract infection within 2 weeks of the Screening Visit.
- •7.Patients at risk of non-compliance.
- •8.Participation in any other clinical study within the previous 3 months.
- •9.Patients with a past or current disease, which as judged by the investigator, may affect the patient’s participation in or the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, immunological disease and endocrine disease.
- •10.Patients treated with beta-blockers or under continuous corticotherapy.
- •11.Allergic sensitivity to epithelial allergens (cats or any other animals) the patient is exposed to in his / her regular environment.
- •12.Positive skin prick test for environmental allergens such as house dust mites and cockroaches, and suffering from serious allergic symptoms due to exposure to these allergens during the study period.
- •13.The intention to subject the patient to surgery of the nasal cavity during the current study.
- •14.The usual contraindications of immunotherapy such as the following:
- •Malignancies and serious disorders of the oral cavity.
- •History of status asthmaticus and anaphylactic shock.
- •Aggressively developing asthmatic symptoms.
- •Serious chronic inflammations, chronic disorders associated with fever, particularly of the bronchial tubes.
- •Irreversible, secondary changes in reactive organs (emphysema, bronchiectasis).
- •Auto-immune diseases and immunodeficiency.
- •Concurrent therapy involving immunosuppressives.
- •Systemic and collagen diseases.
- •Tuberculosis.
- •Serious psychological disorders.
- •Documented hypersensitivity to glycerol.
- •Use of beta-blockers.
- •15.A clinical history of symptomatic seasonal allergic rhinitis and / or asthma due to tree pollen or weed pollen adjacent to the start of, and potentially overlapping, the grass pollen season.
- •16.A clinical history of significant symptomatic perennial allergic rhinitis and / or asthma caused by an allergen to which the patient is regularly exposed.
- •17.Patients at risk of being infected with hepatitis B, hepatitis C or human immunodeficiency virus.
- •18.Patients who received blood in the previous 3 months.
- •19.Patients with a history of drug or alcohol abuse.
- •20.Family members of investigators, co-investigators, and all the study collaborators should not be enrolled in the study.
- •Note: Skin prick test for grass pollen and other allergens: a washout period of 3 days is required for any antihistamines. However, for desloratadine or loratadine, the washout period must be a minimum of 10 days.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RARheumatoid arthritisEUCTR2006-004140-23-DEMerck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitisEUCTR2007-001454-77-FRStallergenes S.A486
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to adult patients suffering from house dust mite allergic rhinitisEUCTR2007-001454-77-CZStallergenes S.A486
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to children suffering from grass pollen rhinoconjunctivitisEUCTR2005-002502-34-DKStallergenes S.A.300
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III follow-up study to assess long-term efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in patients with grass pollen related allergic rhinoconjunctivitis (follow-up study to AB0602). - NAAllergic rhinoconjunctivitisEUCTR2007-002477-31-DEArtu Biologicals Europe B.V.560